Neuropathic agents and pain. New strategies

Biomedicine and Pharmacotherapy

Volumn 60, Issue 7, 2006, Pages 318-322

  Chong, M S ^a   Brandner, B ^b  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Anti depressant; Anti epileptic; Neuropathic pain; Opioids

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CITALOPRAM; DEXTROMETHORPHAN; DULOXETINE; ETIRACETAM; FLUOXETINE; GABAPENTIN; KAPPA OPIATE RECEPTOR AGONIST; KETAMINE; LAMOTRIGINE; METHADONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OPIATE; OXCARBAZEPINE; PAROXETINE; PHENYTOIN; POTASSIUM CHANNEL STIMULATING AGENT; PREGABALIN; SODIUM CHANNEL BLOCKING AGENT; TOPIRAMATE; TRAMADOL; TRAZODONE; UNINDEXED DRUG; VENLAFAXINE; ZONISAMIDE; NARCOTIC ANALGESIC AGENT;

ALZHEIMER DISEASE; ANKLE EDEMA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DIZZINESS; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; EEG ABNORMALITY; EPILEPSY; FIBROMYALGIA; HUMAN; LONG TERM CARE; LOW DRUG DOSE; NEUROPATHIC PAIN; NONHUMAN; PHANTOM PAIN; POSTHERPETIC NEURALGIA; PRESCRIPTION; PRIORITY JOURNAL; SIDE EFFECT; SOMNOLENCE; TRIGEMINUS NEURALGIA; UNITED KINGDOM; WEIGHT REDUCTION; NEURALGIA; PAIN; REVIEW;

ANALGESICS, OPIOID; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; HUMANS; NEURALGIA; PAIN;

EID: 33747892904     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2006.06.016     Document Type: Article

References (40)

1. Dworkin R.H., Backonja M., Rowbotham M.C., Allen R.R., Argoff C.R., Bennett G.J., et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch. Neurol. 60 11 (2003) 1524-1534
2. Berger A., Dukes E.M., and Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J. Pain 5 3 (2004) 143-149
3. Woolf, Clifford J., and Pain M.D. Moving from symptom control toward mechanism-specific pharmacologic management. Ann. Intern. Med. 140 6 (2004) 441-451
4. Sharma U., Young L., and LaMoreaux L. Efficacy, safety and tolerability of pregabalin treatment for neuropathic pain: findings from 11 clinical trials (2005), American Pain Soc, Boston (S29)
5. Richter R., Portenoy R., Sharma U., LA Moreaux L., Bockbrader D.H., and Knapp L.E. Relief of painful diabetic peripheral neuropathy with pregabalin-a randomised placebo-controlled trial. J. Pain (2005) 253-260
6. Lesser H., Sharma U., La Moreaux L., and Poole R.M. Title: Pregabalin relieves the symptoms of diabetic neuropathy-a randomised controlled trial. Neurology 14 (2004) 21042-22110
7. Rosenstock J., Tuchman M., LA Moreaux, and Sharma U. Pregabalin for the treatment of painful diabetic neuropathy-a double-blinded placebo-controlled trial. Pain 110 (2004) 628-638
8. Sabadowski R., Galvez R., Cherry D.A., Jacquot F., Vincent E., Maisonope P., et al. 1008-045 Study Group. Pregabalin reduces pain and improves mood disturbances in patients with post herpetic neuralgia, results of a randomised placebo-controlled clinical trial. Pain 109 (2004) 26-35
9. Dworkin R.H., Corbin A.E., Young Jr. J.P., Sharma U., LaMoreaux L., Bockbrader H., et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 60 8 (2003) 1274-1283
10. Freynhagen R., Strojek K., Griesing T., Whalen E., and Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 115 3 (2005) 254-263
11. Thienel U., Neto W., Schwabes K., and Vijapurk R. U-Topiramate Diabetic Neuropathic Pain Study Group. Topiramate in painful diabetic polyneuropathy-findings from three double-blind controlled trials. Acta Neurologica Scandinavia 110 (2004) 221-231
12. Raskin P., Donofrio P.D., Rosenthal N.R., Hewitt D.J., Jordan D.M., Xiang J., et al. CAPSS-141 Study Group. Topiramate vs. placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology 63 5 (2004) 865-873
13. Chong M.S., and Libretto S.E. The rationale and use of topiramate for treating neuropathic pain. Clin. J. Pain 19 1 (2003) 59-68
14. Price M.J. Levetiracetam and the treatment of neuropathic pain: three case studies. Clin. J. Pain 20 (2004) 33-36
15. Zakrzewska J.M., and Patsalos P.N. Long-term cohort study comparing medical (oxcarbazepine) and surgical management of intractable trigeminal neuralgia. Pain 95 3 (2002) 259-266
16. Hasegawa H. Utilisation of zonisamide in patients with chronic pain or epilepsy refractory to other treatments: retrospective open-label uncontrolled study in a VA hospital. Curr. Med. Res. Opin. 20 (2004) 577-580
17. Rowbotham M.C., Goliv, Kunz N.R., and Lei D. Venlafaxine extending release in the treatment of painful diabetic neuropathy: a double-blind placebo-controlled study. Pain 110 (2004) 697-706
18. Wilson R.C. The use of low-dose trazodone in the treatment of painful diabetic neuropathy. Am Podiatr Med Assoc. 89 9 (1999) 468-471
19. Arnold L.M., Lui Y., Crawford L.J., Wohlreich M., Detkem J., Iyengar S., et al. Double-blind multi-centre trial comparing duloxetine with placebo in the treatment fibromyalgia patients with or without major depressive disorder. Arthritis and Rheumatology 50 (2004) 284-297
20. Dühmke RM, Cornblath DD, Hollingshead JRF. Tramadol for neuropathic pain. The Cochrane Database of Systematic Reviews 2004, Issue 2. Art No.: CD003726. DOI: 10.1002/14651858.CD003726
21. Watson C.P., Moulin D., Watt-Watson J., Gordon A., and Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 105 1-2 (2003) 71-78
22. Gimbel J.S., Richards P., and Portenoy R.K. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 60 6 (2003) 927-934
23. Watson C.P., and Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 50 6 (1998) 1837-1841
24. Breivik H. Opioids in chronic non-cancer pain, indications and controversies. Eur. J. Pain 9 (2005) 127-130
25. Hocking G., and Cousins M.J. Ketamine in chronic pain management: an evidence-based review. Anesth. Analg. 97 6 (2003) 1730-1739
26. Wiech K., Kiefer R.T., Topfner S., Preissl H., Braun C., Unertl K., et al. A placebo-controlled randomized crossover trial of the N-methyl-d-aspartic acid receptor antagonist, memantine, in patients with chronic phantom limb pain. Anesth. Analg. 98 2 (2004) 408-413
27. Sang C.N., Booher S., Gilron I., Parada S., and Max M.B. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiology 96 5 (2002) 1053-1061
28. Ben Abraham R., Marouani N., and Weinbroum A.A. Dextromethorphan mitigates phantom pain in cancer amputees. Ann. Surg. Oncol. 10 3 (2003) 268-274
29. Carlsson K.C., Hoem N.O., Moberg E.R., and Mathisen L.C. Analgesic effect of dextromethorphan in neuropathic pain. Acta Anaesthesiol. Scand. 48 3 (2004) 328-336
30. Cohen S.P., Chang A.S., Larkin T., and Mao J. The intravenous ketamine test: a predictive response tool for oral dextromethorphan treatment in neuropathic pain. Anesth. Analg. 99 6 (2004) 1753-1759
31. Wood P.L. The NMDA receptor complex: a long and winding road to therapeutics. IDrugs 8 3 (2005) 229-235
32. Blackburn-Munro G., Dalby-Brown W., Mirza N.R., Mikkelsen J.D., and Blackburn-Munro R.E. Retigabine: chemical synthesis to clinical application. CNS Drug Rev. 11 1 (2005) 1-20
33. Wood J.N., Boorman J.P., Okuse K., and Baker M.D. Voltage-gated sodium channels and pain pathways. J. Neurobiol. 61 1 (2004) 55-71
34. Liang J., Brochu R.M., Cohen C.J., Dick I.E., Felix J.P., Fisher M.H., Garcia M.L., Kaczorowski G.J., Lyons K.A., Meinke P.T., Priest B.T., Schmalhofer W.A., Smith M.M., Tarpley J.W., Williams B.S., Martin W.J., and Parsons W.H. Discovery of potent and use-dependent sodium channel blockers for treatment of chronic pain. Bioorg Med Chem Lett 15 11 (2005 Jun 2) 2943-2947
35. Staats P.S., Yearwood T., Charapata S.G., Presley R.W., Wallace M.S., Byas-Smith M., et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 291 1 (2004) 63-70
36. Liu X.J., and Salter M.W. Purines and pain mechanisms: recent developments. Curr. Opin. Investig. Drugs 6 1 (2005) 65-75
37. Tsuda M., Inoue K., and Salter M.W. Neuropathic pain and spinal microglia: a big problem from molecules in "small" glia. Trends Neurosci. 28 2 (2005) 101-107
38. Wu G., Whiteside G.T., Lee G., Nolan S., Niosi M., Pearson M.S., et al. A-317491, a selective P2X3/P2X2/3 receptor antagonist, reverses inflammatory mechanical hyperalgesia through action at peripheral receptors in rats. Eur. J. Pharmacol. 504 1-2 (2004) 45-53
39. Rothstein J.D., Patel S., Regan M.R., Haenggeli C., Huang Y.H., Bergles D.E., et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433 7021 (2005) 73-77
40. Gilron I., Bailey J.M., Tu D., Holden R.R., Weaver D.F., and Houlden R.L. Morphine, gabapentin, or their combination for neuropathic pain. N. Engl. J. Med. 352 13 (2005) 1324-1334